Biotech & Research

Dallas – September 12, 2026 -- NFL All-Pro Micah Parsons has taken an equity stake and board seat at RejuvStem, a Cancún, Mexico-based regenerative wellness company, as the firm looks to widen its footprint beyond athletic recovery into the broader preventive health market.

Parsons moves from endorsement to equity investor and board member

The deal, negotiated by Athletes First, the sports representation and marketing agency that handles Parsons' on- and off-field business, gives him formal roles as investor, board member and brand ambassador rather than a standard sponsorship arrangement. He will advise RejuvStem on brand growth and strategic initiatives, working to position the company's regenerative therapies and personalized wellness programs to a wider consumer base that includes non-athletes seeking preventive care.

Berlin – September 11, 2026 -- German Cancer Aid (Deutsche Krebshilfe) collected roughly 4.6 million euros in donations during a televised charity quiz special broadcast on public broadcaster ZDF.

Celebrity contestants earn 80,000 euros in quiz duels against subject experts

Actors Moritz Bleibtreu and Henning Baum, alongside model Franziska Knuppe, competed on "Der Quiz-Champion - Das Spenden-Special," hosted by Johannes B. Kerner, against five specialists: Anna Thalbach, Johann Lafer, Felix Neureuther, Elton and Katrin Bauerfeind. The three celebrities' combined quiz performance generated 80,000 euros for German Cancer Aid.

New Haven, Connecticut – September 07, 2026 -- Yale School of Medicine (YSM) has secured close to $25 million in research funding from the Aligning Research to Impact Autism (ARIA) program, part of ARIA's Human Neurodevelopment Research Centers initiative. The funding will support efforts to build a foundational atlas and model of human brain development, pinpointing when autism-related developmental differences first emerge and how they diverge from typical developmental trajectories.

SHERIDAN, WYOMING - April 14, 2026 - NeuroSense Therapeutics, a clinical-stage drug development company, is positioning itself to address what it characterizes as the "huge unmet need" among patients with amyotrophic lateral sclerosis (ALS). Founded specifically to tackle ALS from a differentiated angle, the company states that this "devastating disease must be addressed from a new perspective," signaling a departure from established therapeutic frameworks. NeuroSense maintains dedicated research and community programs and has published at least four updates between December 2024 and May 2025, indicating sustained development activity. The company's tagline, "New Hope on The Horizon," underscores a patient-focused posture embedded within its clinical-stage mandate.

SHERIDAN, WYOMING - April 14, 2026 - bitBiome, a data and AI company specializing in microbial genomics, is positioning its single-cell sequencing platform as infrastructure for the emerging bioeconomy. The company sequences, catalogs, and evolves microbial genomes from natural environmental samples, producing a proprietary database it describes as the world's most diverse at 2 billion sequences and growing. By combining that dataset with AI-driven bioinformatics and strain engineering, bitBiome addresses the expanding industrial demand for novel enzymes across pharmaceuticals, sustainable materials, and food production. The platform is designed to reduce cost and time-to-result relative to conventional microbial discovery workflows.

SHERIDAN, WYOMING - April 14, 2026 - The ISS National Laboratory has opened applications for its 2026 Orbital Edge Accelerator, a structured startup program that combines private capital with direct access to low Earth orbit research infrastructure aboard the International Space Station. The program offers participating founders $500,000 to $750,000 in private capital alongside mentorship from investors and industry leaders. It marks the organization's latest move to position LEO as an active commercial and industrial domain, building on a record-breaking year for ISS-based scientific output reported in January 2026.

SHERIDAN, WYOMING - April 14, 2026 - Illumina has announced the acquisition of SomaLogic, describing the deal as a unification that will deliver a powerful portfolio of proteomics solutions. The move extends Illumina's core sequencing and array business into protein-level biology, a domain increasingly central to translational research, drug discovery, and clinical diagnostics. Combined with Illumina's existing NGS-based proteomics services offered through the Illumina Protein Prep solution, the acquisition adds significant depth to the company's multiomics ambitions. For laboratory operators and life science research institutions, the deal raises the prospect of sourcing genomic and proteomic workflows from a single integrated vendor.

SHERIDAN, WYOMING - December 30, 2025 - ALS Northwest says it increased its financial investment in ALS research throughout 2025, expanding support for new approaches in treatment, prevention, and scientific understanding while joining a multi-organization funding initiative intended to strengthen the overall research pipeline.

Research investment strategy and portfolio focus

ALS Northwest framed its 2025 approach as a scaled-up commitment to research designed to accelerate innovation in amyotrophic lateral sclerosis (ALS). The organization said its efforts span multiple stages of scientific discovery, with an emphasis on enabling new approaches that could move the field forward. For research stakeholders, the operational question is not only how much is invested, but how efficiently funding is converted into validated findings, new targets, and ultimately clinical progress.

SHERIDAN, WYOMING - December 19, 2025 - Bristol Myers Squibb (BMS) has struck a potential $1B-plus partnership with Harbour BioMed to collaborate on next-generation multi-specific antibody programs, underscoring how China-based innovation is increasingly shaping global biologics dealmaking.

Deal scope and economics in brief
BMS will pay $90 million upfront to work with Harbour on developing and advancing multi-specific antibody therapies, with additional development and commercial milestones that could total up to $1.035 billion. The partners did not disclose how many programs are covered, nor did they specify initial targets, indications, or therapeutic areas.

For business development teams and portfolio planners, the structure reflects a familiar "platform-plus-programs" model: BMS buys early discovery leverage and optionality, while Harbour positions itself for milestone upside and downstream royalties if programs progress.

SHERIDAN, WYOMING - December 19, 2025 - Voyager Therapeutics is laying off 30 employees after partner Novartis discontinued two undisclosed discovery-stage programs under the companies' gene therapy collaboration, underscoring how quickly platform-driven R&D bets can be reprioritized even inside marquee pharma partnerships.

Commercial partnerships can shift overnight
Voyager disclosed last month that Novartis had stepped away from two early programs tied to their ongoing relationship, without naming the assets or detailing the rationale. The biotech framed the change as manageable, stating that Novartis' decision will "not impact Voyager's cash runway guidance." Still, the workforce reduction signals that operational resets often follow partnership scope changes-especially when programs are preclinical and the near-term value is concentrated in a smaller set of advancing assets.